Snuffing Out the Fear of a Lung Cancer Diagnosis
Lung cancer screening is critical for individuals who are at risk for the disease, according to Jeffrey Kwon, MD, a pulmonologist at Bridgeport Hospital, which offers expert care through its Thoracic Oncology Program for patients diagnosed with lung cancer.Source: Yale New Haven Health
ADAURA Update: Osimertinib Benefit in Early NSCLC Sustained
An updated analysis of the phase III ADAURA trial revealed a median disease-free survival (DFS) of 5.5 years for early-stage, EGFR-positive non-small cell lung cancer (NSCLC) patients who received osimertinib (Tagrisso) in the postoperative setting, with nearly three in four patients treated with the adjuvant therapy free of disease at 4 years.Source: MED Page Today
Future Directions in the Management of Non–Small Cell Lung Cancer Harboring Driver Mutations
It has been 20 years since the discovery of EGFR mutations and almost 25 years since we first used EGFR inhibitors in the clinic. This resulted in a paradigm shift regarding the way we think about lung cancer. Now that we have drugs which target growth factor receptors, and we use them to slow the growth of tumors, giving rise to dramatic responses.Source: Cancer Network
‘Game-Changing’ Drug Enhertu Now Approved for Certain Types of Lung Cancer — What Does This Mean for Patients?
A targeted therapy called Enhertu, which recently scored a major approval when it comes to treating advanced breast cancer, has now been given the green light by the Food and Drug Administration (FDA) to treat a certain type of lung cancer as well.Source: Survivornet
Roy S. Herbst, MD, PhD, Examines the Use of Ramucirumab Plus Pembrolizumab in ICI-Resistant Advanced NSCLC
At ASCO 2022, Roy S. Herbst, MD, PhD, reviews a substudy of the phase 2 Lung-MAP trial which investigates ramucirumab plus pembrolizumab for patients with advanced non–small cell lung cancer who demonstrated resistance to previous immunotherapy.Source: Cancer Network
ASCO 2032: What Will Be the Big Story in Lung Cancer?
New clinical research unveiled at the recent American Society of Clinical Oncology (ASCO) annual meeting has the potential to significantly alter the treatment of lung cancer. But what will be the innovations we are talking about in 5 years? Or 10 years? In this last of four exclusive episodes, MedPage Today brought together three leaders in the field -- moderator Roy S. Herbst, MD, PhD, of Yale Cancer Center in New Haven, Connecticut, is joined by Jorge Nieva, MD, of the Keck School of Medicine of USC in Los Angeles, and Sarah Goldberg, MD, also of Yale Cancer Center -- for a roundtable discussion on how to get to the next level in lung cancer, and what they and other experts will hopefully be talking about at ASCO over the next decade.Source: MedPage Today
Top Takeaways in Lung Cancer From ASCO 2022
share to facebook share to twitter share to linkedin email article Play VideoPlay Mute Remaining Time -4:25 CaptionsFullscreen The American Society of Clinical Oncology (ASCO) annual meeting is the stage for presenting many of the most impactful advancements in cancer research -- including in lung cancer. In this second of four exclusive episodes, MedPage Today brought together three leaders in the field -- moderator Roy S. Herbst, MD, PhD, of Yale Cancer Center in New Haven, Connecticut, is joined by Jorge Nieva, MD, of the Keck School of Medicine of USC in Los Angeles, and Sarah Goldberg, MD, also of Yale Cancer Center -- for a roundtable discussion reviewing the most influential lung cancer research presented during the meeting and providing insights on how the new data will influence clinical practice.Source: Medpage Today
Yale Pathology to be Represented at the Pulmonary Pathology Society Meeting in Cork, Ireland
Sanja Dacic, MD, PhD, Vice Chair and Director of Anatomic Pathology at Yale Pathology and president of the Pulmonary Pathology Society (PPS), will be accompanied by the Yale Thoracic Pathology Service team at the PPS Biennial Meeting June 25-27 in Cork, Ireland.
Neoadjuvant Chemo Plus Immunotherapy in Resectable NSCLC
share to facebook share to twitter share to linkedin email article At the recent American Society of Clinical Oncology (ASCO) annual meeting, updated data were presented on the CheckMate 816 trial, a phase III study looking at the efficacy and safety of adding the immune checkpoint inhibitor nivolumab (Opdivo) to neoadjuvant chemotherapy in patients with operable lung cancer.Source: Medpage Today